Literature DB >> 20657750

MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells.

Robert Steele1, Justin L Mott, Ratna B Ray.   

Abstract

c-myc promoter binding protein (MBP-1) is a multi-functional protein known to regulate expression of targets involved in the malignant phenotype. We have previously demonstrated that exogenous expression of MBP-1 inhibits prostate tumor growth, although the mechanism of growth inhibition is not well understood. We hypothesized that MBP-1 may modulate microRNA (miRNA) expression for regulation of prostate cancer cell growth. In this study, we demonstrated that exogenous MBP-1 upregulates miR-29b by 5-9 fold in prostate cancer cells as measured by real-time quantitative reverse transcription-PCR. Subsequent studies indicated that exogenous expression of miR-29b inhibited Mcl-1, COL1A1, and COL4A1. Further, a novel target with potential implications for invasion and metastasis, matrix metallopeptidase-2 (MMP-2), was identified and confirmed to be a miR-29b target in prostate cancer cells. Together our results demonstrated that exogenous expression of miR-29b regulates prostate cancer cell growth by modulating anti-apoptotic and pro-metastatic matrix molecules, implicating therapeutic potential of miR-29b for prostate cancer inhibition.

Entities:  

Year:  2010        PMID: 20657750      PMCID: PMC2908325          DOI: 10.1177/1947601910371978

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  35 in total

1.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

2.  Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas.

Authors:  N Théret; O Musso; B Turlin; D Lotrian; P Bioulac-Sage; J P Campion; K Boudjéma; B Clément
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

3.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.

Authors:  M Krajewska; S Krajewski; J I Epstein; A Shabaik; J Sauvageot; K Song; S Kitada; J C Reed
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

4.  Carboxyl-terminal repressor domain of MBP-1 is sufficient for regression of prostate tumor growth in nude mice.

Authors:  Asish K Ghosh; Robert Steele; Ratna B Ray
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

5.  MBP-1 mediated apoptosis involves cytochrome c release from mitochondria.

Authors:  Asish K Ghosh; Mainak Majumder; Robert Steele; Ta-Jen Liu; Ratna B Ray
Journal:  Oncogene       Date:  2002-04-25       Impact factor: 9.867

6.  Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.

Authors:  B Brehmer; S Biesterfeld; G Jakse
Journal:  Prostate Cancer Prostatic Dis       Date:  2003       Impact factor: 5.554

7.  MBP-1 inhibits breast cancer growth and metastasis in immunocompetent mice.

Authors:  Tatsuo Kanda; Amit Raychoudhuri; Robert Steele; John E Sagartz; Cheri West; Ratna B Ray
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1.

Authors:  Shogo Kobayashi; Sun-Hee Lee; Xue W Meng; Justin L Mott; Steven F Bronk; Nathan W Werneburg; Ruth W Craig; Scott H Kaufmann; Gregory J Gores
Journal:  J Biol Chem       Date:  2007-04-25       Impact factor: 5.157

10.  Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo.

Authors:  S Krajewski; S Bodrug; M Krajewska; A Shabaik; R Gascoyne; K Berean; J C Reed
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

View more
  62 in total

Review 1.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

2.  Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction.

Authors:  Jeffrey A Jones; Robert E Stroud; Elizabeth C O'Quinn; Laurel E Black; Jeremy L Barth; John A Elefteriades; Joseph E Bavaria; Joseph H Gorman; Robert C Gorman; Francis G Spinale; John S Ikonomidis
Journal:  Circ Cardiovasc Genet       Date:  2011-10-18

Review 3.  Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.

Authors:  Cristina Correia; Sun-Hee Lee; X Wei Meng; Nicole D Vincelette; Katherine L B Knorr; Husheng Ding; Grzegorz S Nowakowski; Haiming Dai; Scott H Kaufmann
Journal:  Biochim Biophys Acta       Date:  2015-03-27

4.  Interactome of miRNAs and transcriptome of human umbilical cord endothelial cells exposed to short-term simulated microgravity.

Authors:  Dharanibalan Kasiviswanathan; Rajadurai Chinnasamy Perumal; Srinivasan Bhuvaneswari; Pavitra Kumar; Lakshmikirupa Sundaresan; Manuel Philip; Sajesh Puthenpurackal Krishnankutty; Suvro Chatterjee
Journal:  NPJ Microgravity       Date:  2020-07-30       Impact factor: 4.415

Review 5.  Epigenetic basis of cancer health disparities: Looking beyond genetic differences.

Authors:  Aamir Ahmad; Shafquat Azim; Haseeb Zubair; Mohammad Aslam Khan; Seema Singh; James E Carter; Rodney P Rocconi; Ajay P Singh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-01-17       Impact factor: 10.680

6.  A combined approach identifies three mRNAs that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.

Authors:  Chen Wang; Chao Gao; Jun-Long Zhuang; Chao Ding; Yong Wang
Journal:  J Cancer Res Clin Oncol       Date:  2012-08-05       Impact factor: 4.553

7.  ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.

Authors:  Chi-Ling Chiang; Swagata Goswami; Frank W Frissora; Zhiliang Xie; Pearlly S Yan; Ralf Bundschuh; Logan A Walker; Xiaomeng Huang; Rajeswaran Mani; Xiaokui M Mo; Sivasubramanian Baskar; Christoph Rader; Mitch A Phelps; Guido Marcucci; John C Byrd; L James Lee; Natarajan Muthusamy
Journal:  Blood       Date:  2019-05-31       Impact factor: 22.113

8.  Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity.

Authors:  Peng Ru; Robert Steele; Eddy C Hsueh; Ratna B Ray
Journal:  Genes Cancer       Date:  2011-07

9.  Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: a pilot study.

Authors:  D Pastuszak-Lewandoska; J Kordiak; K H Czarnecka; M Migdalska-Sęk; E Nawrot; D Domańska-Senderowska; J M Kiszałkiewicz; A Antczak; P Górski; E Brzeziańska-Lasota
Journal:  Med Oncol       Date:  2016-07-22       Impact factor: 3.064

Review 10.  miRNAs regulate expression and function of extracellular matrix molecules.

Authors:  Zina Jeyapalan Rutnam; Thomas N Wight; Burton B Yang
Journal:  Matrix Biol       Date:  2012-11-15       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.